SCHEDULE: Forbion Entities Report 5.1% Stake in Aura Biosciences

ForGrowth III PA B.V., along with affiliated entities, reports beneficial ownership of 5,248,841 shares, representing 5.1% of Aura Biosciences' common stock.

Summary

• This filing is a Schedule 13G, indicating a change in beneficial ownership of Aura Biosciences, Inc. common stock.
• The reporting persons are ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V., all organized in the Netherlands.
• Collectively, these entities beneficially own 5,248,841 shares of Aura Biosciences' common stock.
• This ownership represents approximately 5.1% of the outstanding common stock.
• The number of outstanding shares as of August 6, 2026, was reported as 103,704,809.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without new strategic or financial information.

Positives

• The reporting entities have acquired a significant stake, indicating confidence in Aura Biosciences' potential.
• The filing clearly states the exact number of shares owned and the percentage of the class.

Negatives

• No new financial performance data or strategic updates are provided in this filing.
• The filing does not offer insights into the reasons for the acquisition or future investment plans.

Risks

• The filing does not explicitly mention any risks.
• Potential risks could include market volatility affecting the value of the investment and changes in Aura Biosciences' business performance.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Aura Biosciences' future performance. It solely reports on beneficial ownership.

Management Comments

• The Reporting Persons may be deemed to constitute a 'group' within the meaning of Section 13(d)(3) of the Exchange Act, but disclaim membership in a group and this report shall not be deemed an admission.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors or other entities. The 5.1% ownership by Forbion entities suggests a significant but likely non-controlling interest in Aura Biosciences, a biotechnology company.

Stakeholder Impact

• Shareholders: The acquisition of a 5.1% stake by a new entity may signal investor interest, potentially influencing market perception.
• Management: The filing confirms a significant institutional investor's presence, which could lead to increased engagement on governance or strategy.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• The reporting persons will continue to monitor their investment in Aura Biosciences.
• Future filings will be made if ownership levels change significantly.

Key Dates

Keywords

Aura Biosciences, Schedule 13G, Beneficial Ownership, Forbion, Investment, Common Stock, Netherlands